tiprankstipranks
Trending News
More News >
REPRO-MED Systems (KRMD)
NASDAQ:KRMD
US Market
Advertisement

REPRO-MED Systems (KRMD) AI Stock Analysis

Compare
287 Followers

Top Page

KRMD

REPRO-MED Systems

(NASDAQ:KRMD)

Rating:59Neutral
Price Target:
$4.50
▲(9.76% Upside)
KRMD's overall score is driven by strong earnings call highlights and positive technical indicators, offset by weak financial performance and valuation concerns. The company's growth prospects are promising, but profitability and valuation issues remain significant risks.
Positive Factors
Financial Performance
KRMD delivered a strong quarter as it generated $10M in quarterly revenues for the first time and beat across the P&L, continuing to see material outperformance in its OUS markets.
International Expansion
KRMD is expanding its products with a next-gen pump and a new flow controller designed to open new global markets and accelerate revenue growth, reinforcing its competitive advantage in the SCIg market.
Revenue Growth
KRMD raised its revenue guidance reflecting growth of now 15-17%, underpinned by SCIg market growth, global share gains, NRE revenue from new expected collaborations, flow controller line extension, and Japan market entry.
Negative Factors
Competitive Pressures
There is wariness of the potential for competitive pressures to expand going forward.

REPRO-MED Systems (KRMD) vs. SPDR S&P 500 ETF (SPY)

REPRO-MED Systems Business Overview & Revenue Model

Company DescriptionREPRO-MED Systems, Inc. (KRMD) is a medical technology company specializing in the development and manufacturing of innovative medical devices and solutions for the healthcare sector. The company focuses primarily on the area of infusion therapy, providing products that improve the delivery of medications to patients with chronic conditions. Its core products include the proprietary infusion pump system, the FREEDOM60, designed for subcutaneous drug delivery, and other related accessories. REPRO-MED Systems operates in the medical device sector, targeting patients requiring home healthcare solutions, as well as healthcare providers and institutions.
How the Company Makes MoneyREPRO-MED Systems generates revenue through the sale of its medical devices, primarily the FREEDOM60 infusion system and its associated accessories. The company's revenue model is based on direct sales to healthcare providers, distributors, and patients, as well as potential recurring revenue from consumable products related to its infusion systems. Key revenue streams include the initial sale of infusion pumps and ongoing sales of disposable components that require regular replacement. Additionally, partnerships with healthcare organizations and networks can enhance distribution capabilities and broaden market access, contributing to the company's overall earnings.

REPRO-MED Systems Earnings Call Summary

Earnings Call Date:Aug 06, 2025
(Q2-2025)
|
% Change Since: |
Next Earnings Date:Nov 05, 2025
Earnings Call Sentiment Positive
The earnings call reflected strong growth in revenue, international expansion, and positive developments in product pipelines and cash flow management. However, the gross margin decline and anticipated challenges with U.S. distributor inventory reductions present areas of concern. Overall, the positive aspects significantly outweigh the negatives.
Q2-2025 Updates
Positive Updates
Record Revenue Milestone
KORU Medical Systems achieved over $10 million in revenue for Q2 2025, marking more than a 20% year-over-year growth.
Significant International Expansion
International revenues grew by 34%, driven by expansion into new geographies and success with the prefilled syringe strategy in Europe.
Pharma Services and Clinical Trials Growth
The Pharma Services and Clinical Trials segment saw a 42% growth, driven by clinical trial orders from a non-Ig partner.
FDA Approvals and Submissions
FDA approved an expanded indication for Empaveli, and a 510(k) submission was made ahead of schedule for a rare disease biologic.
Positive Cash Flow Trajectory
Q2 cash usage was reduced to $600,000, with expectations for neutral to positive cash flow in the second half of 2025.
Next-Generation Product Developments
Launched Phase I flow controller ahead of schedule and on track with next-gen pump development, with a 510(k) submission expected by Q4 2025 to Q1 2026.
Negative Updates
Gross Margin Decline
A 150-basis point decline in gross margin year-over-year, affected by tariffs and prior year favorable inventory revaluation adjustments.
U.S. Distributor Inventory Reduction
An expected inventory reduction by a large U.S. distributor in Q3, which may impact domestic revenue temporarily.
Company Guidance
During the KORU Medical Systems second quarter 2025 financial results conference call, the company reported a historic milestone with over $10 million in revenue, reflecting a 21% growth year-over-year. The domestic core revenues reached $7.1 million, marking a 15% increase, while international core business revenues grew by 34% to $2.2 million. The Pharma Services and Clinical Trials segment saw a 42% revenue growth, totaling $900,000. Gross margins declined by 150 basis points to 63.5%, affected by tariff impacts and prior year inventory adjustments. However, the company maintained a strong cash balance of $8.1 million, with a cash usage of $600,000 for the quarter. KORU raised its revenue guidance for 2025 to $39.5 to $40.5 million, indicating an 18% to 20% growth and anticipates achieving positive cash flow from operations for the full year. The guidance reflects confidence in international market expansion and pharmaceutical services growth, despite anticipated domestic distributor inventory reductions in Q3.

REPRO-MED Systems Financial Statement Overview

Summary
REPRO-MED Systems is experiencing revenue growth, but consistent losses and negative cash flows pose significant challenges. While the balance sheet shows a stable equity base and manageable debt levels, the company must address its operational inefficiencies to improve profitability and cash generation. Strategic cost management and revenue enhancement are crucial for future financial health.
Income Statement
55
Neutral
The company shows a consistent growth trajectory in revenue with a 5% increase from the previous period to TTM. However, it struggles with profitability as evidenced by negative EBIT and net profit margins, indicating operational inefficiencies and high costs relative to revenue. The gross profit margin remains healthy, suggesting some control over direct costs.
Balance Sheet
60
Neutral
The balance sheet reflects a moderate debt-to-equity ratio of 0.22, indicating prudent leverage. However, the return on equity is negative due to consistent net losses, which is a concern. The equity ratio of 60% indicates a solid capital structure with more equity financing, providing some financial stability.
Cash Flow
50
Neutral
Cash flow analysis reveals challenges, as the company has negative operating cash flow and free cash flow, indicating potential liquidity issues. The free cash flow growth rate improved slightly, but remains negative, highlighting ongoing cash management challenges. The operating cash flow to net income ratio is unfavorable due to persistent losses.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue36.85M33.65M28.52M27.90M23.49M24.18M
Gross Profit23.27M21.33M16.71M15.37M13.77M14.94M
EBITDA-3.77M-5.56M-9.40M-10.19M-6.57M1.61M
Net Income-4.52M-6.07M-13.74M-8.66M-4.56M-1.21M
Balance Sheet
Total Assets25.52M27.22M28.46M42.33M41.29M39.92M
Cash, Cash Equivalents and Short-Term Investments8.05M9.58M11.48M17.41M25.33M27.32M
Total Debt3.47M3.99M4.45M4.93M604.14K239.49K
Total Liabilities8.99M10.40M8.11M11.01M4.79M3.76M
Stockholders Equity16.53M16.81M20.35M31.33M36.50M36.16M
Cash Flow
Free Cash Flow-2.17M-1.62M-5.71M-8.21M-4.69M-1.80M
Operating Cash Flow-682.14K-319.72K-4.89M-5.40M-4.32M-743.32K
Investing Cash Flow-1.53M-1.33M-814.60K-2.80M-366.17K-1.04M
Financing Cash Flow-194.03K-248.53K-218.87K279.49K2.71M23.22M

REPRO-MED Systems Technical Analysis

Technical Analysis Sentiment
Positive
Last Price4.10
Price Trends
50DMA
3.74
Positive
100DMA
3.31
Positive
200DMA
3.47
Positive
Market Momentum
MACD
0.13
Positive
RSI
54.91
Neutral
STOCH
12.24
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KRMD, the sentiment is Positive. The current price of 4.1 is below the 20-day moving average (MA) of 4.15, above the 50-day MA of 3.74, and above the 200-day MA of 3.47, indicating a neutral trend. The MACD of 0.13 indicates Positive momentum. The RSI at 54.91 is Neutral, neither overbought nor oversold. The STOCH value of 12.24 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for KRMD.

REPRO-MED Systems Risk Analysis

REPRO-MED Systems disclosed 48 risk factors in its most recent earnings report. REPRO-MED Systems reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

REPRO-MED Systems Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
77
Outperform
$197.09M16.4410.39%1.98%-16.64%-13.64%
70
Outperform
$217.13M44.819.39%8.13%1293.06%
59
Neutral
$190.03M-25.63%19.57%61.81%
51
Neutral
$7.91B-0.36-41.71%2.23%23.45%-1.86%
51
Neutral
$23.83M-10.80%-0.24%50.45%
40
Underperform
$48.75M-123.50%7.84%-43.00%
$170.80M-69.80%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
KRMD
REPRO-MED Systems
4.10
1.63
65.99%
INFU
InfuSystem Holdings
10.63
4.47
72.56%
RVP
Retractable Technologies
0.78
-0.13
-14.29%
UTMD
Utah Medical Products
62.75
-2.25
-3.46%
MLSS
Milestone Scientific
0.62
-0.40
-39.22%
MBOT
Microbot Medical
3.37
2.49
282.95%

REPRO-MED Systems Corporate Events

Executive/Board ChangesShareholder Meetings
REPRO-MED Systems Holds Annual Shareholder Meeting
Neutral
May 15, 2025

On May 14, 2025, REPRO-MED Systems held its Annual Meeting of Shareholders where key decisions were made regarding the company’s governance and financial oversight. Shareholders elected the proposed nominees to the board of directors, approved executive compensation on an advisory basis, and ratified the appointment of Cherry Bekaert LLP as the independent registered public accountants for the 2025 fiscal year.

The most recent analyst rating on (KRMD) stock is a Hold with a $4.50 price target. To see the full list of analyst forecasts on REPRO-MED Systems stock, see the KRMD Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 14, 2025